CONTENTS

9 FORECAST: ISCHEMIC STROKE (Published on 02 July 2018)
9 OVERVIEW
10 MARKET OVERVIEW AND TRENDS
14 MARKET DEFINITION AND METHODOLOGY
20 PRIMARY RESEARCH METHODOLOGY
22 BIBLIOGRAPHY
23 PRODUCT PROFILE: ASPIRIN
29 PRODUCT PROFILE: PLAVIX

42 TREATMENT: ISCHEMIC STROKE (Published on 14 December 2016)
42 OVERVIEW
43 EXECUTIVE SUMMARY
44 PRIMARY RESEARCH METHODOLOGY
46 DISEASE DEFINITION AND DIAGNOSIS
56 CURRENT TREATMENT OPTIONS
60 PRESCRIBING TRENDS

73 EPIDEMIOLOGY: STROKE (Published on 31 March 2017)
73 OVERVIEW
74 EXECUTIVE SUMMARY
76 DISEASE BACKGROUND
81 SOURCES AND METHODOLOGY
94 FORECAST: INCIDENCE OF STROKE
109 FORECAST: PREVALENCE OF STROKE
126 EPIDEMIOLOGIST INSIGHT
132 STRENGTHS AND LIMITATIONS
135 APPENDIX: ADDITIONAL SOURCES

137 MARKETED DRUGS: ISCHEMIC STROKE (Published on 02 July 2018)
137 OVERVIEW
138 EXECUTIVE SUMMARY
139 PRODUCT OVERVIEW
141 PRODUCT PROFILE: ACTIVASE
150 PRODUCT PROFILE: AGGRENOX
158 PRODUCT PROFILE: ASPIRIN
164 PRODUCT PROFILE: PLAVIX

177 PIPELINE: ISCHEMIC STROKE (Published on 02 July 2018)
177 OVERVIEW
178 EXECUTIVE SUMMARY
179 CLINICAL PIPELINE OVERVIEW
180 RECENTLY DISCONTINUED DRUGS
190 ADDITIONAL PHARMA INTELLIGENCE PIPELINE RESOURCES

LIST OF FIGURES
11 Figure 1: Ischemic stroke market forecast across the US, Japan, and five major EU markets, by country, 2016–25
12 Figure 2: Ischemic stroke market forecast across the US, Japan, and five major EU markets, by drug, 2016–25
16 Figure 3: Patient-based forecast methodology for ischemic stroke
18 Figure 4: Price sources and calculations, by country
23 Figure 5: Datamonitor Healthcare’s drug assessment summary of Aspirin for ischemic stroke
24 Figure 6: Datamonitor Healthcare’s drug assessment summary of Aspirin for ischemic stroke
26 Figure 7: Aspirin sales for ischemic stroke across the US, Japan, and five major EU markets, by country, 2016–25
35 Figure 8: Plavix for ischemic stroke – SWOT analysis
36 Figure 9: Datamonitor Healthcare’s drug assessment summary of Plavix for ischemic stroke
37 Figure 10: Datamonitor Healthcare’s drug assessment summary of Plavix for ischemic stroke
39 Figure 11: Plavix sales for ischemic stroke across the US, Japan, and five major EU markets, by country, 2016–25
53 Figure 12: Mean percentage of patients presenting with stroke-like symptoms diagnosed with particular indications, by country, 2015
60 Figure 13: Mean percentage of ischemic stroke patients receiving each treatment regimen in the US, Japan, and five major EU markets, by country, 2015
62 Figure 14: Mean percentage of ischemic stroke patients receiving each thrombolytic therapy in the US, Japan, and five major EU markets, by country, 2015
64 Figure 15: Mean percentage of ischemic stroke patients receiving each neuroprotective therapy in the US, Japan, and five major EU markets, by country, 2015
66 Figure 16: Ischemic stroke patients receiving the top five antiplatelet/anticoagulant medications in the acute treatment setting, by country, 2015
68 Figure 17: Ischemic stroke patients receiving the top five antiplatelet/anticoagulant medications in the secondary prevention setting at first-line, by country, 2015
70 Figure 18: Mean percentage of ischemic stroke patients who progress to second-line treatment in the secondary prevention setting, by country, 2015
71 Figure 19: Ischemic stroke patients receiving the top five antiplatelet/anticoagulant medications in secondary prevention setting at second-line, by country, 2015
97 Figure 20: Trend in diagnosed incident cases of ischemic stroke in the US, Japan, and five major EU markets, by country, 2016–36
101 Figure 21: Trend in diagnosed incident cases of hemorrhagic stroke in the US, Japan, and five major EU markets, by country, 2016–36
102 Figure 22: Absolute change in diagnosed incident cases of ischemic stroke in the US, Japan, and five major EU markets, by country, 2016–36
103 Figure 23: Absolute change in diagnosed incident cases of hemorrhagic stroke in the US, Japan, and five major EU markets, by country, 2016–36
113 Figure 24: Trend in diagnosed prevalent cases of ischemic stroke in the US, Japan, and five major EU markets, by country, 2016–36
117 Figure 25: Trend in diagnosed prevalent cases of hemorrhagic stroke in the US, Japan, and five major EU markets, by country, 2016–36
118 Figure 26: Absolute change in diagnosed prevalent cases of ischemic stroke in the US, Japan, and five major EU markets, by country, 2016–36
119 Figure 27: Absolute change in diagnosed prevalent cases of hemorrhagic stroke in the US, Japan, and five major EU markets, by country, 2016–36
145 Figure 28: Activase for ischemic stroke – SWOT analysis
146 Figure 29: Datamonitor Healthcare’s drug assessment summary of Activase for ischemic stroke
147 Figure 30: Datamonitor Healthcare’s drug assessment summary of Activase for ischemic stroke
154 Figure 31: Aggrenox for ischemic stroke – SWOT analysis
155 Figure 32: Datamonitor Healthcare’s drug assessment summary of Aggrenox for ischemic stroke
156 Figure 33: Datamonitor Healthcare’s drug assessment summary of Aggrenox for ischemic stroke
158 Figure 34: Datamonitor Healthcare’s drug assessment summary of Aspirin for ischemic stroke
159 Figure 35: Datamonitor Healthcare’s drug assessment summary of Aspirin for ischemic stroke
161 Figure 36: Aspirin sales for ischemic stroke across the US, Japan, and five major EU markets, by country, 2016–25
170 Figure 37: Plavix for ischemic stroke – SWOT analysis
171 Figure 38: Datamonitor Healthcare’s drug assessment summary of Plavix for ischemic stroke
172 Figure 39: Datamonitor Healthcare’s drug assessment summary of Plavix for ischemic stroke
174 Figure 40: Plavix sales for ischemic stroke across the US, Japan, and five major EU markets, by country, 2016–25

LIST OF TABLES
13 Table 1: Distribution of total market sales across ischemic stroke subgroups, 2016–25
14 Table 2: Summary of drug classes and molecules included in Datamonitor Healthcare’s ischemic stroke patient-based forecast
14 Table 3: Patent expiries occurring within the ischemic stroke market during the forecast period, 2016–25
19 Table 4: Exchange rates used for calculating prices
20 Table 5: Cardiologists and neurologists surveyed for the ischemic stroke primary research study, 2015
27 Table 6: Aspirin franchise sales for ischemic stroke across the US, Japan, and five major EU markets, by country ($m), 2016–25
30 Table 7: Plavix drug profile
32 Table 8: Plavix pivotal trial data in ischemic stroke
34 Table 9: Plavix ongoing late-phase clinical trials in ischemic stroke
40 Table 10: Plavix sales for ischemic stroke across the US, Japan, and five major EU markets, by country ($m), 2016–25
44 Table 11: Cardiologists and neurologists surveyed for the ischemic stroke primary research study, 2015
47 Table 12: Overview of risk factors for a first transient ischemic attack or ischemic stroke
50 Table 13: Mean percentage of ischemic stroke patients that have co-morbidities in the US, Japan, and five major EU markets, by country, 2015
51 Table 14: Common transient ischemic attack and ischemic stroke symptoms
52 Table 15: Overview of tests used in ischemic stroke and transient ischemic attack patients, by major category
57 Table 16: Treatments available for ischemic stroke across the US, Japan, and five major EU markets
61 Table 17: Mean percentage of ischemic stroke patients receiving each type of therapy in the US, Japan, and five major EU markets, by country, 2015
63 Table 18: Overview of inclusion and exclusion criteria for patients eligible for alteplase treatment in the US
67 Table 19: Mean percentage of ischemic stroke patients that progress to secondary prevention in the US, Japan, and five major EU markets, by country, 2015
82 Table 20: Sources used for the epidemiological analysis of stroke incidence in the US, Japan, and five major EU markets, by country
85 Table 21: Sources used for the epidemiological analysis of stroke prevalence in the US, Japan, and five major EU markets, by  country
95 Table 22: Diagnosed incident cases of ischemic stroke in the US, Japan, and five major EU markets, by country, 2016–36
99 Table 23: Diagnosed incident cases of hemorrhagic stroke in the US, Japan, and five major EU markets, by country, 2016–36
104 Table 24: Age-specific diagnosed incident cases of ischemic stroke in the US, Japan, and five major EU markets, by country, 2016
105 Table 25: Age-specific diagnosed incident cases of hemorrhagic stroke in the US, Japan, and five major EU markets, by country, 2016
106 Table 26: Gender-specific diagnosed incident cases of ischemic stroke in the US, Japan, and five major EU markets, by country, 2016
107 Table 27: Gender-specific diagnosed incident cases of hemorrhagic stroke in the US, Japan, and five major EU markets, by country, 2016
110 Table 28: Diagnosed prevalent cases of ischemic stroke in the US, Japan, and five major EU markets, by country, 2016–36
115 Table 29: Diagnosed prevalent cases of hemorrhagic stroke in the US, Japan, and five major EU markets, by country, 2016–36
121 Table 30: Age-specific diagnosed prevalent cases of ischemic stroke in the US, Japan, and five major EU markets, by country, 2016
122 Table 31: Age-specific diagnosed prevalent cases of hemorrhagic stroke in the US, Japan, and five major EU markets, by country, 2016
123 Table 32: Gender-specific diagnosed prevalent cases of ischemic stroke in the US, Japan, and five major EU markets, by country, 2016
124 Table 33: Gender-specific diagnosed prevalent cases of hemorrhagic stroke in the US, Japan, and five major EU markets, by country, 2016
127 Table 34: Age-standardized incidence and mortality per 100,000 person-years for ischemic stroke, by country, 1990 and 2010
128 Table 35: Age-standardized incidence and mortality per 100,000 person-years for hemorrhagic stroke, by country, 1990 and 2010
140 Table 36: Key marketed drugs for ischemic stroke
142 Table 37: Activase drug profile
144 Table 38: Activase pivotal trial data in ischemic stroke
151 Table 39: Aggrenox drug profile
152 Table 40: Aggrenox pivotal trial data in ischemic stroke
153 Table 41: Aggrenox late-phase trial data in ischemic stroke
162 Table 42: Aspirin franchise sales for ischemic stroke across the US, Japan, and five major EU markets, by country ($m), 2016–25
165 Table 43: Plavix drug profile
167 Table 44: Plavix pivotal trial data in ischemic stroke
169 Table 45: Plavix ongoing late-phase clinical trials in ischemic stroke
175 Table 46: Plavix sales for ischemic stroke across the US, Japan, and five major EU markets, by country ($m), 2016–25
180 Table 47: Late-stage compounds that were recently discontinued for ischemic stroke
181 Table 48: Ampyra drug profile
182 Table 49: Ampyra late-phase trial data in ischemic stroke
183 Table 50: Brilinta drug profile
184 Table 51: Brilinta late-phase trial data in ischemic stroke
185 Table 52: Desmoteplase drug profile
186 Table 53: Desmoteplase late-phase trial data in ischemic stroke
187 Table 54: Xarelto drug profile
188 Table 55: Xarelto late-phase trial data in ischemic stroke